Completed OBSERVATIONAL NCT01242098

Real-world Effectiveness of Combination Therapies in Primary Care Asthma Management (Fos/Ser_switch)

Retrospective, Real-life Observational, Matched Cohort Evaluation of the Effectiveness of BDP/FOR (Fostair® 100/6) and FP/SAL (Seretide® 125) in Patients Switching From Seretide to Fostair in UK Primary Care Asthma Management

Sponsor: Chiesi Farmaceutici S.p.A.

Conditions Asthma

Interventions Fixed dose combination salmeterol / fluticasone Fixed-dose combination beclometasone dipropionate / formoterol

Updated 6 times since 2017 Last updated: Jun 7, 2012 Started: Jan 31, 2008 Primary completion: Dec 31, 2011 Completion: Dec 31, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01242098, this observational or N/A phase trial focuses on Asthma and remains completed. Sponsored by Chiesi Farmaceutici S.p.A., it has been updated 6 times since 2008, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed
Jul 2024 — Sep 2024 [monthly]

Completed
Jan 2021 — Jul 2024 [monthly]

Completed
Jun 2018 — Jan 2021 [monthly]

Completed
Apr 2018 — Jun 2018 [monthly]

Completed

Phase: NA → None

▶ Show 1 earlier version

Jan 2017 — Apr 2018 [monthly]

Completed NA

First recorded

Jan 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Chiesi Farmaceutici S.p.A.
Research in Real-Life Ltd

Data source: Research in Real-Life Ltd

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Cawston, United Kingdom